Unlike N-terminal inhibitors, such as AUY922 and 17-AAG, these C-terminal inhibitors do not increase the expression of HSP27, HSP40, and HSP70, suggesting their efficacy in anti-cancer function [207]. This evidence concerns the gene DNAJB1 and cancer.